,address1,city,state,zip,country,phone,fax,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Mr. William H. Collier', 'age': 62, 'title': 'Pres, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 933011, 'exercisedValue': 0, 'unexercisedValue': 145950}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
1,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Mr. Michael J. McElhaugh', 'age': 48, 'title': 'COO & Chief Bus. Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 606625, 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
2,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Dr. Michael J. Sofia Ph.D.', 'age': 64, 'title': 'Chief Scientific Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 628435, 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
3,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Mr. David C. Hastings CPA', 'age': 61, 'title': 'CFO & Chief Accounting Officer', 'yearBorn': 1961, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
4,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Ms. Lisa M. Caperelli', 'title': 'VP of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
5,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Mr. J. Christopher Naftzger BA, Esq., J.D.', 'age': 55, 'title': 'Gen. Counsel & Chief Compliance Officer', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
6,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Dr. Karen  Sims M.D., Ph.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
7,701 Veterans Circle,Warminster,PA,18974,United States,267 469 0914,267 282 0411,https://www.arbutusbio.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",96,"{'maxAge': 1, 'name': 'Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C.', 'age': 71, 'title': 'Sec.', 'yearBorn': 1951, 'exercisedValue': 0, 'unexercisedValue': 0}",2,6,6,9,6,1693526400,1672444800,86400,4,2.05,2.05,2.0,2.065,2.05,2.05,2.0,2.065,0.0,2.13278,-4.25,1221218,1221218,614395,717310,717310,2.02,2.06,1000,3200,341816256,1.85,3.15,14.523742,2.111,2.52835,0.0,0.0,USD,191374592,0.0,115759870,167556992,5175305,4888707,1690761600,1693440000,0.0309,0.25073,0.37963,8.48,0.041100003,167556992,0.807,2.5278811,1672444800,1703980800,1688083200,-72932000,-0.46,-0.48,1:5,1288828800,8.131,-2.608,-0.04672897,0.14113986,NMS,EQUITY,ABUS,ABUS,Arbutus Biopharma Corporation,Arbutus Biopharma Corporation,1185456600,America/New_York,EDT,327b69f1-b9aa-3465-8efa-89ecddd8ae31,finmb_34160168,-14400000,2.04,6.0,4.0,4.6,4.0,2.0,buy,5,152484000,0.91,-73384000,2043000,6.323,6.474,23535000,1.517,0.148,-0.23783001,-0.50676,-45389000,-42822624,-82542000,-0.673,-2.35547,0.0,-3.1744199,USD,
